c-Myb-Dependent Inositol 1,4,5-Trisphosphate Receptor Type-1 Expression in Vascular Smooth Muscle Cells
I nositol 1,4,5-trisphosphate receptors (IP3Rs) are intracellular Ca 2ϩ channels located primarily in the ER membrane, 1 which may closely appose the nucleus, mitochondria, or plasma membrane store-operated Ca 2ϩ channels to stimulate capacitative Ca 2ϩ entry (CCE). 2, 3 IP3Rs are encoded by 3 separate genes, giving rise to 3 subtypes (IP3R1-3). Additional heterogeneity is created by alternative splicing and homo-or heterotetramerization. Almost all tissues express all 3 IP3R subtypes to various extents, 1 but IP3R1 predominates in adult vascular smooth muscle cells (VSMCs). 4 Proliferation of VSMCs underlies both atherogenesis and restenosis after angioplasty. 5 In mammalian cells, changes in the intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) regulate several steps in cell cycle progression such as G 0 -to-G 1 phase, G 1 -to-S phase, and G 2 -to-M phase transitions, 6 and modulate activity of cyclinE/cdk2 in particular in VSMCs 7 . Cell cycle entry and proliferation can be induced by growth factors and agonists which bring about sustained increases in [Ca 2ϩ ] i attributable to a combination of increased IP3 binding to IP3 receptors, enhanced activity of store-operated Ca 2ϩ channels, and decreased Ca 2ϩ efflux via plasma membrane Ca 2ϩ -ATPase (PMCA) and sarco/endoplasmic reticulum Ca 2ϩ -ATPase (SERCA) Ca 2ϩ pumps. 8, 9 Knockdown of some of these Ca 2ϩ transporters has confirmed their importance in proliferation. For example, PMCA1 knockdown inhibits cell proliferation in a breast cancer cell line. 10 Similarly, in the rat VSMC cell line A7r5, knockdown of IP3R1, but not IP3R3, abolished IP3 induced Ca 2ϩ release (IICR) as well as CCE and arrested proliferation. 11 Other lines of evidence further support a critical role for IP3 and IP3R1 in cell cycle progression. IICR causes M phase-arrested oocytes to reenter cell cycle after fertilization. 12 In sea urchin embryos, IICR initiated nuclear envelope breakdown, metaphase-anaphase transition, and cytokinesis. 13 In mammalian cells, an anti-IP3R1 antibody blocked IICR and cell cycle after fertilization. 14 Thapsigargininduced depletion of IP3-sensitive Ca 2ϩ stores completely inhibited cyclin-A expression, cdk2 activation, DNA synthesis, and G 1 /S transitions in human fibroblasts, 15 and proliferation was reduced in mouse fibroblasts stably expressing truncated IP3R1 mutants. 16 IP3R1 knockdown in T cells blocked [Ca 2ϩ ] i elevation as well as interleukin (IL)-2 induction, implicating IP3R1 in T cell proliferation. 17 Similarly, B cell proliferation also involves IICR. 18 Finally, when normally quiescent rat aortic VSMCs were incubated in serumcontaining medium, their proliferation was accompanied by a marked increase in IP3R1 but not IP3R2 mRNA levels. 19 c-Myb is a transcription factor expressed in diverse cell types including VSMCs. 20 c-Myb is strongly associated with cell proliferation and G 1 /S transitions 21 and functions via binding to a consensus DNA sequence (TAAC T/G T/G) in the promoters of Myb-dependent genes. 22 c-Myb is known to regulate the promoters of key cell cycle genes such as c-myc (5 Myb binding sites 23 ), cyclin A1, and cdk1 (2 sites each 24, 25 ), proliferation-enabling enzymes such as DNA topoisomerase II ␣ and methionine adenosyltransferase-2A (1 site each 26, 27 ), a G protein-coupled receptor (adenosine receptor 2B; 33 sites 28 ) involved in endothelial cell proliferation, and Ca 2ϩ transporters such as PMCA1 (2 sites 29 ) known to be involved in VSMC proliferation. We and others have previously shown that c-Myb-dependent transcription has a significant role in regulating [Ca 2ϩ ] i at the G 1 /S transition of VSMCs 9, 29, 30 . We have shown that c-Myb represses both PMCA1 and PMCA4 expression at the G 1 /S interface of VSMCs and that this decrease in expression of Ca 2ϩ -efflux pumps enables the increased [Ca 2ϩ ] i required for S-phase entry and cell proliferation. 9,29 -31 Given our initial finding herein of increased IP3R1 mRNA expression levels at the G 1 /S transition of VSMCs, and that c-Myb is capable of both activating 23, 25, 26 and repressing transcription, 29, 32 we hypothesized that cell cycle-regulated expression of the IP3R1 gene may also be mediated by c-Myb-dependent transcription.
In examining the IP3R1 promoter sequences from human, chimpanzee, mouse, rat, cow, and dog genomes, we discovered the presence of multiple putative c-Myb binding sites at conserved positions in all 6 species. We found IP3R1 mRNA expression levels in mouse VSMCs to be responsive to positive and negative regulation of c-Myb expression, and that these 2 proteins undergo coincident upregulation in proliferating mouse VSMCs in vivo. With a 3.1-Kb mouse IP3R1 promoter fragment, reporter assays using deletion and point mutants of this promoter, c-Myb modulating constructs, electrophoretic mobility shift (EMSA), and chromatin immunoprecipitation (ChIP) assays, we present compelling evidence of c-Myb-dependent activation of IP3R1 transcription during G 1 to S cell cycle progression in both primary and immortalized VSMCs.
Methods

Animal Protocols
All experiments were conducted with 12-week-old C57Bl/6J mice and in accordance with approved institutional operating protocols.
VSMC Isolation and Cell Lines
Isolation of primary mouse aortic VSMCs and derivation of our clonal cell line "MOVAS" has been described 31 (#CRL-2797, ATCC, Manassas, Fla). Early Northern blot experiments employed the Syrian hamster ductus deferens SMC cell line (DDT-MF2; ATCC, Manassas, Fla).
Carotid Artery Injury
Carotid artery injury or sham surgery was performed as previously described. 33 
Functional Myb Knockdown
For details regarding the anti-c-Myb antibody construct (pNuMybsFv) 34 see supplemental Methods, available online at http://atvb.ahajournals.org.
Immunostaining
For details regarding reporter constructs, antibodies, and staining protocols used see supplemental Methods. EGFP, Texas red, and Alexa Fluor images were captured using the Olympus IX/81 Fluoview confocal microscope (Olympus America). Cell boundaries were delineated from 5 or more observation fields on each cover slip (nՆ15 cells from 2 separate experiments) in vitro and on each of 3 randomly selected sections per animal (nՆ15 cells), and 3 animals per group (sham versus injured) in vivo. Cell fluorescent intensity was quantified at 15 planes in 15 m wide z-stacks using Olympus FV1000 software.
Calcium Imaging
See supplemental Methods for details.
Ribonuclease Protection Assays
Total RNA was isolated (Nucleospin II, Takara Clontech) from G 0 and G 1 /S stage MOVAS as described. 31 A 370 bp IP3R1-specific probe (Ϫ179 to ϩ191) was PCR cloned (see supplemental Table I for all primer sequences). RPA was carried out (Kit III; Ambion) and protected bands were aligned with the sequencing ladders generated from the reverse primer used to clone the probe (Sequenase kit; Amersham).
Quantitative RT-PCR
Total RNA was extracted from G 0 -and G 1 /S-synchronized MOVAS either nontransfected or electroporated (Protocol A-033: 10 6 cells, 5 g DNA/cuvette; VSMC kit; Amaxa) with pNuMybsFv and a c-Myb responsive promoter-luciferase reporter (mim1-luc; J. Lipsick, Stanford University). Total RNA was also extracted from G 0 -and G 1 /S-synchronized primary VSMCs isolated from C57Bl6 mouse aortas, which were either nontransfected or electroporated with mim1-luc and various IP3R1 promoter-luciferase constructs. DNasetreated RNA samples were each spiked with 0.1 pg of in vitro transcribed EGFP RNA as a control for efficiency of cDNA synthesis and used in quantitative PCR (SYBR GREEN; Applied Biosystems; supplemental Table I) for IP3R1, luciferase, EGFP, and ␤-2 microglobulin, a housekeeping gene used as an internal control. 35 IP3R1 and luciferase mRNA copy numbers were normalized to EGFP and ␤-2 microglobulin mRNA copy numbers and finally to their respective mean G 0 mRNA levels.
Cloning, Deletion and Point Mutations of the Mouse IP3R1 Promoter
See supplemental Methods for full details.
Promoter Luciferase Assay
MOVAS cells were transfected (Lipofectamine; Invitrogen) with either a promoterless luciferase vector (pGL3-Basic; Promega, Madison, WI) or the IP3R1 promoter-driven luciferase vector with or without c-Myb-modulating cDNA constructs expressing either a dominant negative c-Myb, 30 the anti-c-Myb antibody, 34 or wild-type mouse c-Myb. 36 See supplemental Methods for further details.
Electrophoretic Mobility Shift Assays
G 1 /S stage MOVAS cells were used to make nuclear protein extracts as described. 29 EMSA was carried out 32 using 32 P-end labeled, gel purified double stranded oligos (supplemental Table  I ). Double stranded oligos used correspond to the native (C57Bl/ 6J) and point mutated Myb-13 and -15 c-Myb binding sites in the mouse IP3R1 promoter (GenBank Accession # AY857958; supplemental Figure III ). 
Chromatin Immunoprecipitation
Statistics
Luciferase assays, immunostaining quantification, Ca 2ϩ microfluorimetry, and real time RT-PCR data are shown as meansϮSEM and represent results from at least 3 separate experiments (nՆ3). Student t test was used for statistical comparisons. Statistical significance was defined as PՅ0.05.
Results c-Myb Modulates Cell Cycle-Regulated Expression of IP3R1
Having previously shown cell cycle-regulated [Ca 2ϩ ]i in VSMCs, 30 we first examined whether IP3R-responsive Ca To ascertain whether IP3R1 expression levels were regulated in proliferating VSMCs in vivo, we examined injured mouse carotid arteries (supplemental Figure II) . At day 9 after surgery, proliferating medial VSMCs exhibited a 77Ϯ9% increase in IP3R1 immunostaining in injured versus unin- Taken together, the above data revealed cell cycle-associated regulation of UTP-defined IP3R1 activity and c-Mybresponsive expression levels of IP3R1 mRNA and protein in vitro, with coincident upregulation of c-Myb and IP3R1 protein expression in proliferating VSMCs in vivo. Table II) .
Conserved Structure of the IP3R1 Promoter
Mikoshiba et al previously reported a transcriptional start for IP3R1 at #2524 in mouse neuronal cells (GenBank Acc. #D78171). 37 We carried out 2 independent ribonuclease protection assays on RNA from G 0 -and G 1 /S-synchronized MOVAS. Identical sized RNase protected bands were observed in RNA samples from G 0 -and G 1 /S-synchronized MOVAS, revealing transcriptional start (ϩ1) in VSMCs at position #2526 (supplemental Figure IV) . A 1.0-Kb mouse IP3R1 promoter sequence (Ϫ500 to ϩ500) was used to search for IP3R1 promoter sequences from rat, human, chimpanzee, dog, and cow on ENSEMBL Genome Browser. Promoter sequences corresponding to Ϫ2526 to ϩ614 were downloaded from each of these species and scanned for putative Myb binding sites using MatInspector. 38 Comparisons revealed that all 6 mammalian species have the transcriptional start sequence CAGTAA (experimentally confirmed in mouse), a TATA sequence 29 to 31 bp upstream, and multiple putative c-Myb-binding sites upstream and downstream of transcriptional start. Notably, only Myb site-13 from the mouse IP3R1 promoter was conserved in all mammalian IP3R1 promoters analyzed (Figure 3) .
Activation of the IP3R1 Promoter Requires Multiple Intact c-Myb-Binding Sites
When the mim-1-luc construct (containing 3 copies of the mim-1 Myb binding site upstream of a minimal promoter) was transfected into MOVAS ( Figure 4A Deleting various regions of the 3.1-Kb IP3R1 promoter and testing luciferase reporter activity suggested that transcriptional start was flanked by two important regulatory regions: an upstream region from Ϫ2500 to Ϫ2000 and a downstream region from ϩ100 to ϩ600, both containing putative c-Myb binding sites (supplemental Figure V , sites 1 to 6 upstream and sites 13 to 17 downstream of transcriptional start). When Myb sites 1 to 6, or 1 to-11, were deleted, G 1 /S-specific IP3R1 promoter activity decreased to 0.57Ϯ0.32 and 0.75Ϯ0.15 (PϽ0.05) of G 0 levels (G 0 ϭ1.00), respectively, compared with 2.20Ϯ0.15 (PϽ0.05) for the wild-type promoter. Deletion of Myb sites 15 to 17, or 13-to 17, decreased G 1 /S-specific IP3R1 promoter activity to 0.12Ϯ0.05 (PϽ0.05) and 0.22Ϯ0.11 (PϽ0.05), respectively, pointing to a more significant contribution. Promoter deletants harboring only Myb sites 12 to 14, or 12 alone, exhibited reduced promoter activity (G 1 /Sϭ0.32Ϯ0.07 and 0.37Ϯ0.02, respectively; PϽ0.05 in both cases), suggesting again the importance of both upstream and downstream sequences.
Point mutations in Myb sites 13 and 15 significantly reduced G 1 /S-specific transactivation of the IP3R1 promoter (G 1 /Sϭ0.8Ϯ0.16 and 0.46Ϯ0.12, respectively; PϽ0.05 in both cases; Figure 4C ). However, some Myb sensitivity still remained in these point mutants, as their activity could be further repressed by the Myb-neutralizing antibody. Point mutations in Myb sites 1, 6, and 16/17 had no significant effect on promoter activity (data not shown).
When primary mouse aortic VSMCs were electroporated with a control vector (mim-1-luc; supplemental Figure VI 
Specific c-Myb-Binding Sites in the IP3R1 Promoter
Electrophoretic mobility shift assays (EMSA) with nuclear protein extracts from G 1 /S-synchronized MOVAS cells and radio-labeled double-stranded oligodeoxynucleotides (ds oligos) corresponding to Myb sites 13 and 15 demonstrated that a protein-DNA complex was formed in a dose-dependent fashion with increasing amounts of MOVAS cell protein. These protein-DNA complexes could be competed out with 150-fold excess unlabeled wild-type (nonmutated) ds oligos identical to Myb site 13 or 15, but not with 150-fold excess unlabeled point-mutated ds oligos for Myb site 13 or 15 ( Figure 5 ).
Chromatin immunoprecipitation carried out with an antic-Myb antibody ( Figure 6 ) and primers specific for Myb sites 13 and 15 showed that c-Myb is bound to Myb sites 13 and 15 at the G 1 /S stage in MOVAS cells. Promoters which are normally transcriptionally active in VSMCs but are not regulated by c-Myb (such as the mouse myosin heavy chain promoter's CArG element) were not present in chromatin pulled down with the anti-c-Myb antibody. 
Discussion
Previous work has suggested that Ca 2ϩ signals mediating cell cycle transitions are generated by Ca 2ϩ released from intracellular Ca 2ϩ stores. 39 -41 Indeed, IP3R expression is maintained while L-type Ca 2ϩ channel and RyR expression is lost when quiescent VSMCs undergo a phenotypic switch to the proliferating/synthetic state. 42, 43 Moreover, Wilkerson et al 44 have recently used a cerebral artery organ culture to show that an IP3R-mediated increase in Ca 2ϩ wave frequency is critically required for mouse VSMC proliferation, whereas Wang et al demonstrated that IP3R1 but not IP3R3 knockdown severely inhibits rat VSMC proliferation. 11 Based on the above, our demonstration of c-Myb-dependent IP3R1 promoter transactivation is consistent with that of other c-Myb-responsive genes critically involved in cell proliferation. 23, [25] [26] [27] 37 Most recently, Nakata et al have shown that c-Myb transactivates the human cyclin B1 promoter by binding to the highly conserved ϩ22 c-Myb binding site also found in rat, mouse, and 4 other mammalian species. 45 We have previously shown that repression of the promoter for a Ca 2ϩ efflux pump (PMCA1) contributes to the generation of the late G 1 -associated Ca 2ϩ signal 9, 30 and also that this transcriptional repression is brought about by the binding of c-Myb to 2 specific Myb recognition elements in the PMCA1 promoter. 29 Evidence presented here brings a novel addition to the list of c-Myb target genes involved in Ca 2ϩ -mediated regulation of the cell cycle. Here we show that c-Myb can bring about the transcriptional activation of the IP3R1 promoter at the G 1 /S transition by binding to at least 2 specific c-Myb recognition elements, one of which is highly conserved in the IP3R1 promoters of human, chimpanzee, mouse, rat, dog, and cow.
The findings we have detailed include (1) cell cycleregulated induction of IP3R1 in immortalized and primary VSMCs in vitro and proliferation-associated induction of IP3R1 in injured carotid arteries; (2) downregulation of IP3R1 promoter activity by a dominant negative c-Myb or an anti-c-Myb antibody; (3) multiple putative c-Myb binding sites upstream and downstream of IP3R1 transcriptional start; (4) promoter deletant data supporting regulatory function in both upstream and downstream regions; (5) confirmation via point mutations that Myb-binding sites 13 and 15 play a major role in transactivation in both immortalized and primary VSMCs; and (6) evidence that c-Myb can bind to oligos encoding Myb sites 13 and 15 as well as to these sites in G 1 /S-stage native chromatin. Considering the role of c-Myb in repressing the PMCA1 promoter 29 and activating the IP3R1 promoter (this report), we believe that c-Myb acts to coordinately regulate the promoters of various Ca 2ϩ transporter genes and influences the generation of Ca 2ϩ transients which mediate progression through the VSMC cell cycle. 
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